It remains open to be discovered whether combining NTP with currently available anti-CD47 therapies (e.g., Hu5F9-G4, a humanized IgG4 isotype immune checkpoint inhibitor of CD47) [32,33] will be beneficial or if combination strategies with other checkpoint inhibitors that target a separate axis of anti-cancer immunity are more favorable. Here, CD47 is linked to cancer.